FIELD: biotechnology.
SUBSTANCE: invention relates to a method for reducing the onset or reducing the progression of prostate cancer in a mammal prone to developing prostate cancer, which is established by one or more screening methods for detecting prostate cancer, comprising administering to a prostate cancer susceptible mammal, therapeutically effective amount of recovered peptide consisting of amino acid sequence SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), where the peptide is introduced into the central part of the prostate, in which the cancer is less common, where the method reduces the onset of prostate cancer by more than about 15 % compared to the mammals receiving the placebo, or reduces the progression of prostate cancer to a value which is in the range of about 0 % to less than about 5 %.
EFFECT: disclosed is use of peptide of nerve threads for preventing or reducing progression of prostate cancer.
14 cl, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTING ONSET OR REDUCING INCIDENCE OF ACUTE URINARY RETENTION | 2017 |
|
RU2721538C1 |
| COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL FUNCTION | 2018 |
|
RU2739916C1 |
| METHOD OF REDUCING SEVERITY OR PREVENTING ACERBATION OF PROGRESSION OF SYMPTOMS OF BPH | 2017 |
|
RU2744691C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISORDERS | 2004 |
|
RU2543350C2 |
| METHODS AND COMPOSITIONS FOR GASTROENTERIC UPSET THERAPY | 2004 |
|
RU2353383C2 |
